Evidence map›Paper›PMID 40640100›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2025

[A Case Report of Coexistence of EGFR and ROS-1 Gene Mutations 
in Non-small Cell Lung Cancer].

Juan Zhao, Jiaofeng Yu, Ye Fu, Yan Zhao, Mingli Zhao

Abstract readCase ReportsEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Juan ZhaoKunming Medical University, Kunming 650500, China.
Jiaofeng YuKunming Medical University, Kunming 650500, China.
Ye FuKunming Medical University, Kunming 650500, China.
Yan ZhaoKunming Medical University, Kunming 650500, China.
Mingli ZhaoKunming Medical University, Kunming 650500, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer represents one of the most prevalent malignant tumors globally, and its treatment has entered the era of targeted therapy. The epidermal growth factor receptor (EGFR) mutation is a common type of genetic mutation in non-small cell lung cancer (NSCLC), while c-ros oncogene 1 receptor tyrosine kinase (ROS-1) fusion mutation is a rare mutation site. Currently, there are few case reports on the coexistence of EGFR and ROS-1 gene mutations. This study reports a case of NSCLC with coexisting EGFR and ROS-1 gene mutations, aiming to provide relevant treatment strategies for clinical practice.
.

Indexed as

Carcinoma, Non-Small-Cell LungErbB ReceptorsLung NeoplasmsMutationProtein-Tyrosine KinasesProto-Oncogene ProteinsFemaleHumansMaleMiddle AgedEGFR protein, humanErbB ReceptorsProtein-Tyrosine KinasesProto-Oncogene ProteinsROS1 protein, humanCase reportCo-mutationEGFRLung neoplasmsROS-1

Identifiers

PMID40640100
PMCPMC12257172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.